The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse.
Kurosawa S, Yamaguchi H, Yamaguchi T, Fukunaga K, Yui S, Kanamori H, Usuki K, Uoshima N, Yanada M, Takeuchi J, Mizuno I, Kanda J, Okamura H, Yano S, Tashiro H, Shindo T, Chiba S, Tomiyama J, Inokuchi K, Fukuda T.
Kurosawa S, et al. Among authors: fukunaga k.
Int J Hematol. 2020 Aug;112(2):200-209. doi: 10.1007/s12185-020-02894-x. Epub 2020 Jun 3.
Int J Hematol. 2020.
PMID: 32495317